chemotherapy-induced nausea and vomiting: the role of aprepitant
نویسندگان
چکیده
antiemetics are given to cancer patients prior to their chemotherapy sessions to protect them from nausea and vomiting induced by chemotherapy. the responsible health care team member will choose the type of antiemetic required to prevent the patient from developing nausea and vomiting according to the chemotherapy ematogenicity level. current guidelines recommend using a single antiemetic agent or a combination of antiemetic agents such as a 5-hydroxytrypt-amine3 receptor antagonist, dexamethasone, or the neurokinin-1 receptor antagonist aprepitant. this review discusses the role of aprepitant in preventing and managing nausea and vomiting induced by chemotherapy.
منابع مشابه
Aprepitant for chemotherapy-induced nausea and vomiting.
Although the development of serotonin receptor antagonists has greatly improved treatment for chemotherapy-induced nausea and vomiting, patients receiving chemotherapy continue to experience this troublesome side effect. On March 26, 2003, the U.S. Food and Drug Administration approved aprepitant (Emend, Merck & Co., Inc., Whitehouse Station, NJ) for use in combination with standard antiemetic ...
متن کاملAprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
INTRODUCTION Chemotherapy-induced nausea and vomiting (CINV) represents a significant burden on patients and healthcare systems. Despite the introduction of serotonin antagonists, many patients still experience CINV, particularly delayed symptoms occurring more than 24 hours after chemotherapy. Aprepitant is a selective neurokinin-1 (NK(1)) receptor antagonist approved for use with other antiem...
متن کاملChemotherapy-induced nausea and vomiting.
younger patient age, platinumor anthracyclinebased chemotherapy, low alcohol consumption, earlier cycles of chemotherapy, previous history of morning sickness, and prior emetic episodes after chemotherapy. The acute and delayed scoring systems both had good predictive accuracy when applied to the external validation sample (acute— auroc: 0.69; 95% confidence interval: 0.59 to 0.79; delayed—auro...
متن کاملChemotherapy-induced nausea and vomiting.
Chemotherapy-induced nausea and vomiting (CINV) affects many cancer patients and has a great influence on quality of life. CINV involves coordination of several organs of the gastrointestinal tract, the peripheral and central nervous systems. Many neurotransmitters are involved in this process, and the predominant receptors are serotonin, neurokinin-1 and dopamine receptors. Risk factors for CI...
متن کاملChemotherapy-Induced Nausea and Vomiting
In the past two decades, significant advances have been made in the management of chemotherapy-induced nausea and vomiting (CINV). These advances are primarily due to a greater understanding of the physiological and molecular pathways underlying CINV, which resulted in major progress in the management of patients with CINV. In the early 1990s, CINV treatment consisted of dex-amethasone [1]. Imp...
متن کاملChemotherapy-induced nausea and vomiting.
Nausea and vomiting (N&V) is among the most distressing side effects of chemotherapy, despite the development of more efficacious antiemetic agents. As many as 60% of patients who receive cancer chemotherapy experience some degree of N&V. However, the actual incidence is difficult to determine with accuracy because of the variety of drugs, doses, and health conditions of the patients who receiv...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
middle east journal of cancerجلد ۲، شماره ۱، صفحات ۳-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023